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Abstract: Mucosal healing determined by endoscopy is currently the remission standard for ulcerative
colitis (UC). However, new criteria for remission are emerging, such as histologic normalization,
which appears to correlate better to the risk of relapse. Here, we study mucosal healing on a molecular
and functional level in quiescent UC. We obtained endoscopic biopsies from 33 quiescent UC patients
and from 17 controls. Histology was assessed using Geboes score. Protein and mRNA levels were
evaluated for the tight junction proteins claudin-2, claudin-4, occludin, and tricellulin, as well as
Cl−/HCO3− exchanger DRA, and cyclo-oxygenase enzymes (COX-1, COX-2). The mucosal activity
of COX-1 and COX-2 enzymes was assessed in modified Ussing chambers, measuring electrogenic
ion transport (short-circuit current, SCC). Chronic inflammation was present in most UC patients.
The protein level of claudin-4 was reduced, while mRNA-levels of claudin-2 and claudin-4 were
upregulated in UC patients. Surprisingly, the mRNA level of COX-1 was downregulated, but was
unaltered for COX-2. Basal ion transport was not affected, while COX-2 inhibition induced a two-fold
larger decrease in SCC in UC patients. Despite being in clinical and endoscopic remission, quiescent
UC patients demonstrated abnormal mucosal barrier properties at the molecular and functional
level. Further exploration of mucosal molecular signature for revision of current remission standards
should be considered.
Keywords: Inflammatory bowel disease; ulcerative colitis; mucosal healing; mucosal barrier integrity;
tight junction; short-circuit current; PGE2; COX-1; COX-2
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1. Introduction
Ulcerative colitis (UC) is an idiopathic chronic inflammatory bowel disease (IBD), characterized
by latent periods exacerbated by sudden relapses of activity with abdominal discomfort, increased
stool frequency and rectal bleeding [1].
The primary objective of current management is to alleviate patient symptoms by achieving clinical
remission. The second objective is to achieve endoscopic mucosal healing (eMH), since endoscopic
remission is believed to correlate with improved long-term outcome and lower risk of relapse. The third
objective is to maintain steroid-free remission [1,2].
It is difficult to predict long-term outcomes and relapse of UC with the current remission standards
and available biomarkers. Therefore, better and/or complimentary dynamic, predictive and prognostic
biomarkers are needed.
Several studies have demonstrated that histologic abnormalities may persist despite eMH, [3–6]
and that histologic mucosal healing (hMH, deep remission) is associated with a reduced risk of
relapse and prolongs steroid-free remission [5,7–9]. As such, adjustment of current therapy goals is in
demand, since eMH is questionable as an adequate stand-alone predictive and prognostic biomarker
for long-term outcome and risk of relapse.
Complete mucosal healing includes the normalization of barrier function. The mucosal barrier
function depends mainly on the integrity, and related permeability, of the tight junction (TJ) complex
located apically between epithelial cells. The TJ complex regulates passive paracellular passage of
water and electrolytes and also acts as a barrier preventing passage of microbes and other potentially
harmful molecules like lipopolysaccharides and other antigens [10]. The composition of the TJ proteins,
both their expression patterns and distribution, and therefore “tightness” of the tissue, varies between
organs and is influenced by various external stimuli such as pathogenic effector cytokines [10–12].
There is an association between UC disease activity and increased mucosal permeability, which is
theorized to be an important pathogenic factor in IBD [13,14]. During active UC disease, the integrity of
the mucosal barrier is compromised by an altered TJ structure. These alterations include reduced strand
count and depth [15], downregulation of tightening proteins like claudin-4, occludin and tricellulin, and
upregulation of channel-forming claudin-2, thereby leading to increased leakiness of mucosa [12,16,17].
Changes occur during the recurrent inflammatory response and are key hallmarks of UC.
Further, seeking to correct the level of cyclooxygenase (COX) enzyme activity seems necessary for
complete mucosal healing. Eicosanoids derived from arachidonic acid, including prostaglandin E2,
PGE2, are involved in both the promotion and resolution of acute inflammation, and ensuing healing of
mucosa [18]. PGE2 also plays an important role in mucosal homeostasis by inducing chloride secretion,
and is produced via COX-1 (constitutive) and COX-2 (inducible) enzyme activities. COX-2 enzyme
activity is significantly upregulated during intestinal inflammation, thereby increasing the production
of PGE2 [19]. As such, complete mucosal healing (cMH) consists not only of re-establishing mucosal
barrier function, but also a normalization of COX-2 enzyme and its down-stream activities.
The objective of this descriptive study was to explore the concept of molecular/functional remission
as a potential predictive and/or prognostic complementary biomarker of long-term outcome and risk of
relapse. We hypothesized that patients with quiescent UC and mucosal healing defined by endoscopy
and histology may still have disease activity at a molecular and functional level.
We examined mucosal healing at the molecular and functional level by determining mucosal
barrier integrity (TJ protein complex profile and subcellular localization), COX-enzyme activity and ion
transport capacity (basal and stimulated) as compared to clinical, endoscopic and histologic findings
in UC patients with quiescent disease.
2. Results
Seventy-seven individuals were initially included based on clinical appearance. Hereof, 18 (23%
18/77) were excluded during the endoscopic procedure due to colonic polyps, diverticulosis, disease
activity (Mayo endoscopic sub score > 1), or incomplete endoscopy. Three UC patients (8%, 3/36) were
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excluded during the central reading process of endoscopy due to disease activity. Six controls (26%, 6/23)
were excluded after histological examination due to signs of subclinical chronic inflammation. As a
result, we enrolled 33 quiescent UC patients in clinical and endoscopic remission and 17 endoscopically
and histologically healthy controls (Figure 1). There were no apparent important differences between
groups with respect to gender, age, smoking habit or use of medication except for the use of 5-ASA
and other immune modulating medications in UC patients (Table 1).
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Table 1. Study population characteristics.
UC Controls
Total number 33 17
Males/females 15/18 8/9
Age, mean, years (range) 39 (23–75) 46 (20–68)
Smoking habit, active/ex-smoker/never 2/3/28 0/3/14
Maximum disease extent:
Proctitis 7
NA1Colitis 2 26
Disease duration, mean months (range) 118 (3–420) 3
Remission duration, mean months (range) 15 (1–61) 3 NA
Mayo endoscopic sub score, 0/1 24/9 NA
Medication:
No treatment 8 3
5-ASA 17 0
Anti-TNFα 6 0
Immunosuppressants 7 0
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Table 1. Cont.
UC Controls
Corticosteroid 1 0
α4β7 integrin inhibitor 1 0
Vitamin/iron supplements 2 3
Proton-pump inhibitor 0 1
Thiazides 0 2
Statins 0 2
Inhaler (β2-agonist, steroid) 1 3
Thyroid hormone 0 2
Antihistamine 2 1
Contraception 3 2
Anti-epileptic 1 0
1 NA, not applicable. 2 Either left-sided, extensive colitis or pancolitis. 3 Data from 2 patients missing.
2.1. Clinical and Endoscopic Assessment
All 33 UC patients were in clinical and endoscopic remission and had normal stool frequency.
The majority (82%, 27/33) had been in clinical remission for more than 3 months prior to study inclusion.
Most UC patients (73%, 24/33) had a Mayo endoscopic sub score of 0, and only a minority (27%, 9/33)
had a Mayo endoscopic sub score of 1.
2.2. Histological Assessment
Biopsies from all patients were examined histologically and scored according to the Geboes score.
Regardless of the Mayo endoscopic sub score, the majority (66%, 22/33) of the UC patients had signs
of mild to moderate chronic inflammation (defined by increased lymphocyte infiltration and Geboes
score 1.1-1.2), while the remaining (33%, 11/33) patients showed no signs of inflammation (Figure 2).
No acute inflammation, defined primarily as the presence of neutrophils, was observed in any of the
biopsies. All controls presented normal histology.
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Figure 2. Histological features in quiescent ulcerative colitis (UC). H&E staining of colonic mucosal
biopsies (×200 magnification). Two UC patients, both in clinical and endoscopic remission but
with different histologies: (A) No inflammation, (B) chronic inflammation. Blue arrow: increased
chronic inflammatory infiltrate with lymphocytes. Green arrow: Paneth cell metaplasia. Red arrows:
crypt irregularity.
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2.3. Mucosal Integrity Assessment
2.3.1. Protein levels
Figure 3A shows the protein expression of tight junction proteins claudin-2, claudin-4, occludin,
and tricellulin, as well as Cl−/HCO3− exchanger downregulated-in-adenoma (DRA), COX-1 and COX-2
enzymes. UC patients demonstrated a 55% reduced expression of claudin-4 protein level compared
to controls (P = 0.035), while levels of TJ proteins claudin-2, occludin, and tricellulin were unaltered.
Protein levels of COX-1, COX-2 and DRA were also unaltered.
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Figure 3. Western blot and RT-qPCR. (A) Expression levels of barrier related proteins by densitometric
analysis of estern blot ( B). Values are expressed as % of a mean of all controls (ctrls). Bars indicate
mean ± standard error of the mean. Asterisk indicates statistically significant difference between groups
(* p < 0.05). (B) mRNA levels by RT-qPCR. Values are expressed relative to a mean of all controls.
Three controls (18%, 3/17) presented a different baseline of housekeeping genes, while two controls
(12%, 2/17) presented outliers, which were removed, leaving the final number of controls for mRNA
analysis at 12 (70% 12/17). One outlier (3%, 1/33) was removed from the UC group. n = number of UC
observations: COX-1 (n = 16), COX-2 (n = 11), claudin-2 (n = 23), claudin-4 (n = 33), occludin (n = 31),
tricellulin (n = 29), and DRA (n = 33). Bars indicate mean ± standard error of the mean. Asterisks
indicate statistically significant difference between two groups (* p < 0.05, ** p < 0.01).
2.3.2. mRNA levels
Figure 3B shows mRNA expression of the same proteins, where detection was possible. In UC
patients, mRNA levels were significantly upregulated for both claudin-2 (5-fold, P = 0.030) and
claudin-4 (2-fold, P = 0.031). Occludin, tricellulin and DRA mRNA were unaltered. COX-1 mRNA
levels were significantly decreased (2-fold, P = 0.003), while COX-2 was unaltered in UC patients.
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2.3.3. Protein Localization by Fluorescent Immunohistochemistry
We next examined the cellular and subcellular localization of Cl−/HCO3−-exchanger DRA as well
as TJ proteins occludin and claudin-4 in colonic biopsies from 11 UC patients and 11 controls using
fluorescent immunohistochemistry. Localization of claudin-2 in controls was attempted using four
different antibodies without achieving specific staining (see Materials and Methods).
In controls, DRA was localized to the apical microvilli of the surface epithelium (Figure 4A).
In addition to the strong apical localization, a weak intracellular signal was observed in the surface
cells, concentrated around the nucleus and most likely originating from the endoplasmic reticulum.
DRA was noticeably absent from goblet cells. Occludin was detected at the TJ of both surface and
crypt cells, with the strongest expression observed in crypts (Figure 4B). Claudin-4 was detected at
lateral membranes as well as the TJ. The expression was mainly detected in the surface epithelium;
however, a weaker signal was also observed in crypt cells (Figure 4C). In addition to the membrane
localization at lateral membranes and TJ, claudin-4 was occasionally observed in intracellular vesicles
in the surface epithelium (Figure 4C).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 7 of 18 
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Figure 4. The localization of downregulated-in-adenoma (DRA), occludin and claudin-4. Representative
confocal images of human colonic biopsies from control, CTRL, (n = 11) and UC patients (n = 11) stained
for (A) DRA, (B) occludin and (C) claudin-4. Occludin and claudin-4 display intracellular accumulation
in the surface epithelium of a subset of UC patients (white arrows). Stains for Na+/K+-ATPase or
beta-catenin were included to mark the lateral membranes and the nuclei were visualized with DAPI.
The localization depicted for UC patients was observed in the indicated subset of biopsies (2/11, 1/11,
respectively). The upper panels in A–C show low magnification images and below high magnification
images, while the lower panels show high magnification images of the surface epithelium. Scale bars:
upper panel in A–C: 50 µm, lower panels in A–C: 20 µm.
For the major part of analyzed UC biopsies (81%, 9/11 biopsies), no significant changes in the
localization of DRA, occludin and claudin-4 were observed (data not shown). However, for the
remaining two UC biopsies (19%, 2/11), significant alterations in the localization of primarily claudin-4,
but also occludin, were observed. The two UC biopsies were characterized by surface epithelial cells of
low height that displayed substantial accumulation of claudin-4 in intracellular vesicles (Figure 4C).
Similarly, but less significant, accumulation was observed for occludin in one of the two biopsies
(Figure 4B). Interestingly, Na+/K+-ATPase, and to a lesser extent beta-catenin, demonstrated some
vesicular accumulation in the surface epithelium, although both were included as markers of lateral
membranes (Figure 4C). The localization of DRA was not significantly disturbed (Figure 4A).
2.4. Transport Characteristics
Figure 5 illustrates the PGE2–induced secretion pathway, while Figure 6 shows two
examples of mini-Ussing-air-suction (MUAS-chamber) experiments illustrating short-circuit current
(SCC)-responses to pharmacological intervention targeting specific components of the secretion
pathway. The results are listed in Table 2.
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Figure 5. Prostaglandin E2 (PGE2)-dependent chloride (Cl−) secretion in a colonocyte. Cyclooxygenase
enzyme 1 (COX-1) and -2 (COX-2) produce PGE2 from activated arachidonic acid (AAA). PGE2
leaves the cell through the basolateral membrane and exerts its function either by auto- or paracrine
stimulation. Binding to its receptor (EP-receptor) stimulates the synthesis of second messenger cyclic
adenosine monophosphate (cAMP) from adenosine triphosphate (ATP) by adenylate cyclase (AC).
cAMP in turn stimulates luminal Cl− secretion and is degraded to adenosine monophosphate (AMP)
by phosphodiesterase-enzymes (PDE). SC-560 and rofecoxib specifically inhibits COX-1 and COX-2,
while indomethacin is a non-specific COX-inhibitor. Theophylline is a non-specific phosphodiesterase
inhibitor. Amiloride inhibits Epithelial Sodium Channel (ENaC)-mediated luminal sodium absorption.
Chloride influx through basolateral Na+/K+/2Cl−-cotransporter and efflux through apical chloride
channel cystic fibrosis transmembrane conductance regulator (CFTR). PGE2 synthesis also occurs in
the subepithelium. + and – indicate stimulatory and inhibitory effects, respectively.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 9 of 18 
 
 
Figure 6. Examples of short-circuit current (SCC) data. Measurements in biopsies from an UC patient 
(A), and control (B). Biopsies mounted in the mini-Ussing-air-suction (MUAS) chambers were 
exposed to: amiloride (sodium absorption inhibitor, 20 µM), theophylline (non-specific 
phosphodiesterase inhibitor, 400 µM), a specific COX inhibitor (either COX-1, SC-560, or COX-2, 
rofecoxib, 500 nM) followed by indomethacin (non-specific COX inhibitor, 13 µM), prostaglandin E2 
(PGE2) in increasing concentrations (five-step, factor five from 5 to 3125 nM), and ultimately either 
bumetanide (Na+/K+/2Cl⁻-cotransporter inhibitor, 25 µM) or ouabain (Na+/K+-ATPase inhibitor, 200 
µM). 
On average, UC patients demonstrated a 2.5-fold larger decrease in SCC to COX-2 inhibition 
with rofecoxib (P = 0.01), indicating an increased COX-2 activity and elevated levels of PGE2 in UC 
patients (Figure 7). Ten UC patients (35%, 10/28) demonstrated a COX-2 activity distinctly higher 
than in controls, defined as control mean + 2 SD. Half of these (5/10) were UC patients with a Mayo 
endoscopic sub score of 0, while the remaining half had a Mayo endoscopic sub score of 1. The 
decrease in SCC following COX-2 inhibition was similar in UC patients regardless of their status in 
histology-proven chronic inflammation (Figure 7). 
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Figure 6. Examples of short-circuit current (SCC) data. Measurements in biopsies from an UC patient
(A), and control (B). Biopsies mounted in the mini-Ussing-air-suction (MUAS) chambers were exposed to:
amiloride (sodium absorption inhibitor, 20 µM), theophylline (non-specific phosphodiesterase inhibitor,
400 µM), a specific COX inhibitor (either COX-1, SC-560, or COX-2, rofecoxib, 500 nM) followed by
indomethacin (non-specific COX inhibitor, 13 µM), prostaglandin E2 (PGE2) in increasing concentrations
(five-step, factor five from 5 to 3125 nM), and ultimately either bumetanide (Na+/K+/2Cl−-cotransporter
inhibitor, 25 µM) or ouabain (Na+/K+-ATPase inhibitor, 200 µM).
Table 2. Basic SCC and responses to in vitro pharmacological interventions.
Baseline
UC (µA · cm−2) Controls (µA · cm−2) p value
107.6 ± 8.6 a 107.5 ± 16.7 a 0.99
ENaC inhibition −35.1 ± 7.5 b −37.2 ± 8.4 b 0.85
Baseline after ENaC inhibition 70.8 ± 7.5 a 66.0 ± 14.4 a 0.77
Non-specific PDE inhibition 22.0 ± 3.7 b 23.8 ± 5.2 b 0.77
COX-1 inhibition −31.3 ± 3.8 b −26.2 ± 4.7 b 0.40
COX-2 inhibition −51.6 ± 10.5 b −21.0 ± 3.7 b 0.01
PGE2 concentration response EC50 (nM)
Rmax
(µA cm−2) EC50 (nM)
Rmax
(µA cm−2) EC50 (nM) Rmax
High-affinity receptor 14.2 ± 2.7 60.9 ± 5.8 11.0 ± 2.4 52.1 ± 6.9 0.39 0.34
Low-affinity receptor 588.8 ± 106.7 83.1 ± 11.2 493.2 ± 110.6 84.7 ± 13.4 0.54 0.93
First row shows baseline short-circuit current (SCC) measured 10 min after mounting (UC: n = 33, controls: n = 15).
Second row: inhibition of ENaC mediated sodium absorption induces a decrease in SCC (UC: n = 32, controls:
n = 15). Third row: after ENaC inhibition, the new baseline SCC is driven by anion secretion. Fourth row: SCC
increase after non-specific PDE inhibition (UC: n = 31, controls: n = 11). Rows five and six show SCC response
(decrease) to COX-1 (UC: n = 27, controls: n = 12) and COX-2 inhibition (UC: n = 28, controls: n = 11), respectively.
Rows seven and eight include half maximal effective concentration (EC50) and maximal receptor response (Rmax) of
a high- and a low-affinity PGE2 receptor (UC: n = 19, controls: n = 12). SCC is recorded as µA · cm−2. n = number of
patients included in experiment. Due to unstable and/or non-vital biopsies after mounting in MUAS chambers,
not all patients are represented in this section. a Data are shown as mean SCC ± SEM. b Data are shown as mean
∆SCC ± SEM.
On average, UC patients demonstrated a 2.5-fold larger decrease in SCC to COX-2 inhibition with
rofecoxib (P = 0.01), indicating an increased COX-2 activity and elevated levels of PGE2 in UC patients
(Figure 7). Ten UC patients (35%, 10/28) demonstrated a COX-2 activity distinctly higher than in
controls, defined as control mean + 2 SD. Half of these (5/10) were UC patients with a Mayo endoscopic
sub score of 0, while the remaining half had a Mayo endoscopic sub score of 1. The decrease in SCC
following COX-2 inhibition was similar in UC patients regardless of their status in histology-proven
chronic inflammation (Figure 7).
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3. Discussion
The present study provides data suggesting that some patients with quiescent UC disease,
in clinical and endoscopic remission, still maintain signs of disease activity at the molecular and
functional level. With that aspect, we propose to consider and further explore complementing
end scopic and histologic assessment with molecular (structural TJ proteins) and functional (COX
enzyme activity) markers, in order to define complete mucosal healing (cMH), which would be the
ultimate biomarker index and target-to-treat for mucosal healing and predicting long-term outcomes
and risk of relapse.
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3.1. Mucosal Barrier Function
We demonstrate that in quiescent UC, claudin-4 protein level is downregulated, despite
upregulation at the mRNA level, indicating a potential accelerated degradation of the protein.
In support of this, a subset of UC patients displayed displacement of claudin-4 from the cell surface to
intracellular vesicles (Figure 4C).
The mRNA expression of claudin-2 was upregulated with unchanged protein levels, indicating
activity on a molecular level, albeit not detectable using Western blot (WB). Our findings are in line
with Vivinus et al., who demonstrated that the expression of other important TJ proteins (occludin,
ZO-1 and alpha-catenin) was reduced at the level of mRNA in quiescent IBD. The protein levels of TJ
proteins were, however, not measured in their study [20].
A compromised barrier in quiescent UC is likely associated with ongoing clinical symptoms [20–22].
Chang et al. reported that 17% of UC patients suffered from diarrhea and/or abdominal pain despite
endoscopic mucosal healing. They demonstrated an association between symptoms and increased
intestinal permeability evaluated by endoscopic confocal laser endomicroscopy, which is a relatively
novel endoscopic tool measuring fluorescein leakage in vivo, an indirect marker of intestinal barrier
integrity and function [21]. In another study, in patients with Crohn’s disease (CD) in endoscopic
remission, fluorescein leakage proved to be a useful predictor for relapse of CD [23]. So far, no similar
follow up has been reported for UC patients, although Karstensen et al. did observe fluorescein leakage
in 82% of patients with active UC [24]. As such, the data support that an intact mucosal barrier function
is likely to be a reasonable target-to-treat, and that endoscopic confocal laser endomicroscopy has the
potential of being part of the assessment toolbox, together with endoscopy and molecular signatures,
of MH, disease activity and response to therapy.
3.2. Ion Transport and COX-Enzyme Activity
Besides barrier function, we studied the mucosal ion transport properties. In active disease,
epithelial ion transport is impaired in terms of the reduced absorption of sodium through epithelial
sodium channels, ENaC, and chloride through the Cl−/HCO3− exchanger, DRA, while secretion remains
unaltered [25,26]. In agreement with Gustafsson et al., we found no difference in basal ion transport
between patients with quiescent UC vs. controls [27]. Following in vitro drug intervention, we
studied different components of the PGE2-dependent chloride secretion signaling pathway, including,
indirectly, the enzyme activities of COX-1 and COX-2.
Our MUAS experiments on biopsies from a large subset of UC patients in clinical and endoscopic
remission revealed a greater response towards COX-2 inhibition compared to the colon-healthy controls,
indicating increased COX-2 activity as well as elevated levels of PGE2. This corresponds well with our
knowledge of COX-2 being upregulated during active disease and resulting in an increased production
of PGE2 [28,29]. However, the altered epithelial COX-2 activity appears not to be dependent on the
mild to moderate chronic inflammation observed in most UC patients. This indicates basic alterations
in UC patients compared to controls and challenges histology as a stand-alone marker for mucosal
integrity at a deeper level (Figure 7).
Unexpectedly, we found significantly reduced levels of COX-1 mRNA, which might be due to a
decreased population of COX-1-expressing intestinal tuft cells in quiescent UC patients (unpublished
data), although COX-1 protein levels were unaltered. The fact that both the qPCR and WB results
include subepithelial expressions might explain why the results do not reflect epithelial function, as
measured in Ussing chambers (Table 2).
It is important to gain further information on PGE2 receptors, as they mediate PGE2 effects in acute
inflammation and are associated with the development of colorectal cancer as well as other serious
complications related to IBD [18,30]. The application of exogenous PGE2 provided data indicating the
presence of two distinct functional PGE2 receptors, a high- and a low-affinity receptor. Of potential
importance, the high-affinity receptor was sensitive to concentrations of nM PGE2 (EC50 of about
11 nM). We speculated that UC patients have increased sensitivity and higher potency at lower levels
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of PGE2 concentrations and thereby increased activity of the high-sensitive PGE2 receptor. However,
this was not the case in the present small cohort, as high-affinity EC50s were not different between
patient groups (Table 2). With the existence of four PGE2 receptor subtypes, more experiments are
required to relate the two observed receptor subtypes to either of the four receptors.
The implementation of Ussing chamber technique in assessing disease activity alongside
endoscopic and histologic parameters is impractical, but our results illustrate the necessity of reviewing
the current remission standard including molecular and functional markers.
3.3. Limitations of Study
Firstly, the strict patient selection resulted in the notorious inherent slow recruitment process.
Since the final number of included UC patients was low, we had to pool all into one group regardless of
the Mayo endoscopic sub scores. Secondly, several UC patients were referred for only a sigmoidoscopy,
which would not detect polyps or other uncharacteristic non-continuous activity in the right and
transverse segments of the colon. Thirdly, we find no apparent differences in basic characteristics
between groups but, considering the complexity of UC and the many influencing factors, these results
should be confirmed on a larger number of patients. Further, we did not include any information
on the content of dietary consumption and the use of probiotics, which are both important factors in
mucosal healing. Evaluation of such parameters is clearly desirable for future studies on UC.
3.4. Perspectives
The ultimate therapeutic goal is the long-term complete remission of patient signs and symptoms
as well as disease activity biomarkers. For UC, improved mucosal healing (MH) is of particular
importance, as it correlates reversely with risk of progression, developing serious complications and
relapse of disease [31]. However, the definition of MH is being questioned and additional predictive
and prognostic biomarkers are clearly needed.
MH is currently assessed by endoscopy and it is debated whether the assessment of histology
should also be included for disease predictions [8,32,33]. A patient is in “deep remission” if both
endoscopy and histology show normal findings. Whether deep remission is sufficient as a treatment
target or if normalization of additional mucosal functions is needed to improve clinical outcomes and
the course of the disease inclusive of the time to relapse remain open questions.
This study explores potential means of how to define and assess mucosal healing at the
molecular and functional levels. Indeed, it seems appropriate to consider and further explore
such biomarkers as treatment-to-target concepts. From the results of the present study, tight junction
protein claudin-4 expression is a worthwhile readout parameter in particular, eventually being related
to claudin-2 expression.
4. Materials and Methods
4.1. Study Population
UC patients were all in clinical and endoscopic remission, i.e., total Mayo score ≤ 2, and no
sub score > 1, and undergoing routine sigmoid or colonoscopy examination for disease control
and monitoring. The control group consisted of patients referred to colonoscopy on suspicion of
colorectal disease but deemed healthy based on results from endoscopic and histologic examinations.
Patients were excluded from the study if regularly treated with a non-steroidal anti-inflammatory
drug (NSAID), non-selective COX-inhibitor, and/or suffered from other chronic gastrointestinal (GI)
diseases; i.e., dyspepsia, celiac disease, lactose intolerance, irritable bowel syndrome, diverticulosis,
and/or neoplasia coli.
We enrolled 33 UC patients and 17 controls. Four UC patients (12%, 4/33) and eight controls (47%,
8/17) suffered from co-morbidities including hypercholesterolemia, hypothyroidism, asthma, epilepsy,
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primary sclerosing cholangitis, nephrectomy, fibromyalgia, depression, and hypertension. The study
population characteristics and medication are listed in Table 1.
4.2. Biopsy Procedure
Seven sigmoid biopsies were obtained from each patient during endoscopy, approximately 30 cm
proximal to the anal verge on retraction of the endoscope using standard biopsy forceps (Boston
Scientific, Radial Jaw 4, outside diameter of 2.2 mm). Four biopsies were immediately transferred to an
iced bicarbonate Ringer solution with the following composition (in mM): Na+ (140), K+ (3.8), Cl−
(117), Ca2+ (1.0), Mg2+ (0.5), SO42− (0.5), HCO3− (25), and D-glucose (5.5) to be analyzed in MUAS
chambers [34]. Two biopsies were snap-frozen in liquid nitrogen and stored at −80 ◦C for the further
quantification of protein and mRNA expression. One biopsy was preserved in paraformaldehyde for
histological and immunohistochemical examination.
4.3. Chemicals, Antibodies and Primers
All chemicals for the MUAS experiments were purchased from Sigma-Aldrich (Seelze, Germany).
Western blot antibodies for claudin-2 (cat. no.: 51-6100), claudin-4 (cat. no.: 329400), and occludin
(cat. no.: 71-1500) were purchased from Invitrogen (Karlsruhe, Germany); tricellulin (cat. no.:
700191) from Abfinity Thermofisher Science (Karlsruhe, Germany); COX-2 (cat. no.: M3210) from
Spring Biosciences; COX-1 (cat. no.: ABIN343669), SLC26A (DRA; cat. no.: ABIN2777377), and
GAPDH (cat. no.: ABIN3187999) were purchased from Antibodies-online.com. Immunofluorescence
antibodies for claudin-4 (cat. no.: 32-9400) were purchased from Thermo Fisher Scientific (Roskilde,
Denmark); occludin (cat. no.: SC-133265), SLC26A (DRA; cat. no.: SC376187), Beta-catenin (cat. no.:
SC-7963), and Na+/K+-ATPase (cat. no.: SC-28800) were purchased from Santa Cruz Biotechnology
(Heidelberg, Germany). Primers for quantitative reverse transcription-polymerase chain reaction
(qRT-PCR) were ordered from PrimerDesign (Camberley, UK) or Eurofins MWG (Ebersberg, Germany).
The primer sequences used were: COX-1 (PTGS1) forward (5′- TTGGGGAGAGTATGATAGAGATTG
-3′) reverse (5′- CGGAAGGAAACGTAGGGACAG -3′); COX-2 (PTGS2) forward (5′- CAGGCTTCCATT
GACCAGAG -3′) reverse (5′- TTTCTCCTGTAAGTTCTTCAAATGAT -3′); Claudin-2 (CLDN2)
forward (5′- ATCAGTGCCCCATTTGTACC -3′) reverse (5′- TCTCTCTGCCAGGCTGACTT -3′);
Claudin-4 (CLDN4) forward (5′- CGCACAGACAAGCCTTACTC -3′) reverse (5′- CTCAGTCCA
GGGAAGAACAAAG -3′); Occludin (OCLN) forward (5′- AGCAGCGGTGGTAACTTTG -3′)
reverse (5′- AGTTGTGTAGTCTGTCTCATAGTG -3′); Tricellulin (MARVELD2) forward (5′-
GGACAGATAGCTGCAATGATCTTC -3′) reverse (5′- GCTCATTTATCTCCTGTTGTTCCATA -3′);
DRA (SLC26A3) forward (5′- CCAGATCAGCAGTTCAGGAGAG -3′) reverse (5′- CCAGGAGAAA
TCCAATGGCTAGA -3′); GAPDH forward (5′- GAGTCAACGGATTTGGTCGT -3′) reverse (5′-
GACAAGCTTCCCGTTCTCAG -3′).
4.4. Study Methods
Six complementing methods for assessing mucosal status were employed, (A) clinical assessment
and endoscopy, (B) histology, (C) constituent protein levels evaluated by 3 methods: (C.1) protein
expression by WB and densitometric analysis, (C.2) mRNA expression by qRT-PCR, (C.3) localization of
selected proteins by immunofluorescence, and finally (D) transport capabilities by MUAS technique [34].
4.4.1. Clinical Assessment and Endoscopy
Clinical symptoms were scored according to the Mayo score before the endoscopic procedure.
Endoscopies were performed and assessed by local physicians and were filmed and assessed externally
according to the Mayo endoscopic sub score (central reading). Any discrepancy between local and
external readings would turn out in favor for the latter.
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4.4.2. Histology
Biopsies were fixed immediately in paraformaldehyde and then embedded in paraffin. Sections,
4µm thick, were stained with hematoxylin and eosin (H&E). Each biopsy was assessed for inflammatory
activity and scored blindly by a GI expert pathologist according to the Geboes score [3]. Acute
inflammation was defined as the presence of neutrophil infiltration, and chronic inflammation by an
increased lymphocyte infiltration.
4.4.3. Mucosal Proteins and Function
Western Blot
Tissue, suspended in a lysis buffer, 20 mM TRIS, 5 mM MgCl2, 1 mM EDTA, 0.3 mM EGTA,
containing protease inhibitors (cOmplete, Roche, Basel, Switzerland) was homogenized using a
FastPrep24 Homogenizer (MP Biomedicals, Eschwege, Germany), followed by centrifugation at 200× g
for 5 min (at 4 ◦C) and a subsequent centrifugation of the remaining supernatant at 43,000× g for 30 min
(at 4 ◦C). The resulting pellets contained the membrane proteins and were dissolved in resuspension
buffer, 10 mM TRIS-Cl pH 7.5; 150 mM NaCl, 0.5% Triton X-100, 0.1% SDS, and protease inhibitors.
Protein concentrations were determined using BCA Protein assay reagent, Pierce (Perbio Science, Bonn,
Germany), quantified with a plate reader, (Tecan, Crailsheim, Germany). Protein samples of the same
concentrations were prepared and mixed with Laemmli buffer, denatured at 95 ◦C for 5 min, separated
on SDS polyacrylamide gels, and transferred to PVDF membranes, Perkin Elmer (Rodgau, Germany).
Proteins were detected by immunoblotting with primary antibodies against claudin-2 and
claudin-4, occludin, tricellulin, COX-1, COX-2, SLC26A (DRA) and GAPDH. After washing steps in
TBS/0.1% Triton X-100, TBST, membranes were incubated with secondary anti-mouse or anti-rabbit
antibodies. Membranes were washed and incubated with Lumilight, Roche, and specific signals were
detected with a chemiluminescence imager, Fusion FX7, Vilber, and analyzed using a quantification
software, AIDA, Raytest (Straubenhardt, Germany).
mRNA Levels by Quantitative Real-time PCR
RNA was extracted using the RNeasy Mini Kit, Qiagen (Copenhagen, Denmark), following the
manufacturer’s protocol with changes in tissue disruption: up to 30 mg of tissue was placed in a 2 ml
Eppendorf tube together with a metal bead and 350 µL RLT/0.01% v/v 2-mercaptoethanol. The tubes
were placed in a Tissue Lyser, Qiagen (Copenhagen, Denmark), for 3 × 2 min at 50 Hz, and samples
were centrifuged at 8,000× g for 3 min. The supernatant was used for the extraction.
Template cDNA was generated from 500 ng of total extracted RNA using TaqManTM Reverse
Transcription kit, Applied Biosystems (Warrington, UK), according to manufacturer’s instructions in
the presence of RNaseOUT. The following conditions were used for qRT-PCR in a CFX384 TouchTM
Real-Time PCR Detection System, Biorad (Watford, UK): 95 ◦C for 10 min, followed by 45 cycles of
95 ◦C for 15 s and 58 ◦C for 1 min; this was proceeded with 95 ◦C for 15 s, 60 ◦C for 15 s, and finally
95 ◦C for 15 s.
Protein Localization by Fluorescent Immunohistochemistry
Twenty-two biopsies, 11 UC and 11 controls, were fixed in paraformaldehyde, embedded in
paraffin and cut into 4 µm thick sections. The sections were deparaffinized and rehydrated in a
xylene–ethanol series and subjected to antigen retrieval by boiling in 1 mM EDTA pH 8.0 for a total
of 10 min. Unspecific binding was blocked for 30 min in PBS containing 0.1% Triton X-100 and
0.2% fish skin gelatin. Primary antibodies diluted in the same buffer were added overnight at 4 ◦C.
The following antibodies were employed (dilution in parenthesis): mouse anti-occludin (1:100), mouse
anti-SLC26A3 (1:100), mouse anti-beta-Catenin (1:100), rabbit anti-Na+,K+-ATPase (1:100), and mouse
anti-Claudin-4 (1:100). Four antibodies directed against Claudin-2 were tested on control biopsies
without obtaining a specific signal (#32-5600 and #51-6100 from Thermo Fischer Scientific, Roskilde,
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Denmark, #28530 from Cell Signaling Technology, BioNordika, Herlev, Denmark, and sc-293233
from Santa Cruz Biotechnology, Heidelberg, Germany). Bound primary antibodies were detected
by incubation in AlexaFluor®-conjugated secondary antibodies, Thermo Fisher Scientific (Roskilde,
Denmark), for 1 hour at room temperature. Nuclei were detected using 4′6-diamidino-2-phenylindole
(DAPI), Thermo Fisher Scientific (Roskilde, Denmark). Sections were mounted in Prolong Diamond,
Thermo Fisher Scientific (Roskilde, Denmark). Confocal images were acquired with Zeiss LSM
710/LSM780 confocal microscopes using ×20 objective, NA 0.8, or ×63 oil immersion objective, NA
1.4. Pinhole size was 1 airy unit, the pixel format 1024 × 1024 and line averaging was employed to
reduce noise.
4.4.4. Mini-Ussing-Air-Suction (MUAS) Chamber Technique
Within 45 min after collection, the biopsies were mounted in MUAS-chambers as previously
described [34]. Both the serosal and mucosal side were bathed in bicarbonate-Ringer solution.
Baseline electrogenic mucosal ion transport properties (expressed as short-circuit-current, SCC)
before pharmacological intervention were measured approximately 10 min after mounting. Biopsies
were exposed to pharmacological intervention with amiloride (epithelial sodium channel, ENaC,
inhibitor, 20 µM), theophylline (non-specific phosphodiesterase, PDE, inhibitor, 400 µM), indomethacin
(non-selective COX inhibitor, 13 µM), SC-560 (selective COX-1 inhibitor, 500 nM), rofecoxib (selective
COX-2 inhibitor, 500 nM), and to PGE2 in increasing concentrations (5-step, factor 5 from 5 to 3125 nM),
exploring various components of the PGE2–induced secretion pathway. All biopsies were exposed to
bumetanide (Na+/K+/2Cl−-cotransporter inhibitor, 25 µM) and/or ouabain (Na+/K+-ATPase inhibitor,
0.2 mM) at the end of the experiment to verify the viability of the biopsies, judged as an adequate
response due to former manipulations. Amiloride was added to the mucosal side of the biopsies
mounted in MUAS-chambers, while all other compounds, including bumetanide and ouabain, were
added to the serosal side. Luminal chloride secretion was measured as SCC after inhibiting electrogenic
luminal sodium absorption. As such, SCC is a result of the combined activity of enzymes involved in
the signaling cascade. By manipulating a specific component at a time in the pathway, the concomitant
change in SCC was assumed as an indirect measurement for a change in the related enzyme activity.
4.5. Statistical Analysis
Values are expressed as mean ± SEM. Mean values were used if identical experiments on biopsies
from the same patient were performed. Student’s t-test with Welch’s correction was used to identify
differences between two groups, except for densitometric analyses of WB, where we used the t-test
with Bonferroni correction. A p-value < 0.05 was considered significant.
5. Conclusions
Most UC patients in the present study demonstrated histological signs of chronic inflammation
and compromised mucosal barrier functions during quiescent disease. The mucosal barrier and
function signatures included altered TJ protein barrier composition, increases in COX-2 enzyme activity
and related ion transport properties.
Moving forward, we propose to consider and continue evaluating mucosal healing using molecular
and functional markers as potential target-to-treat endpoints, in addition to endoscopic and histological
markers, for UC remission. Our results suggest that particularly assessing claudin-4 expression could
prove useful in this respect.
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Abbreviations
cMH Complete mucosal healing
COX Cyclooxygenase
DRA Downregulated-in-adenoma
EC50 Half maximal effective concentration
ENaC Epithelial sodium channel
eMH Endoscopic mucosal healing
GI Gastro-intestinal
hMH Histological mucosal healing
IBD Inflammatory bowel disease
MH Mucosal healing
MUAS Mini-Ussing-air-suction system
NSAID Non-steroid anti-inflammatory drug
PDE Phosphodiesterase
PGE2 Prostaglandin E2
qRT-PCR Quantitative reverse transcription polymerase chain reaction
Rmax Maximum response
SCC Short-circuit current
SEM Standard error of the mean
SD Standard deviation
TJ Tight junction
UC Ulcerative colitis
WB Western blot
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